VISTA, Calif.--(BUSINESS WIRE)--Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry, has received clearance from the U.S. Food and Drug Administration (FDA) to market the HER2 image analysis application available through its patented ScanScope® slide scanning system. The FDA-cleared immunohistochemistry (IHC) image analysis application is intended to be used as an aid to pathologists in detecting and quantifying HER2 protein expression from digital slide images created by Aperio’s slide scanning systems.
